For all patients, HASS, combined hematologic/oncologic diseases, PIM2, lactate (LAC), platelet (PLT), activated partial thromboplastin time, international normalized ratio, total bilirubin, mechanical ventilation, vasoactive drug therapy, renal replacement therapy, positive pathogen detection, respiratory failure, renal injury, cerebral dysfunction, and MODS were associated with the 28-day mortality rate. The gene discussed is PIM2; the disease is respiratory failure.